The $4.85 billion Vioxx settlement announced last week is bolstering hopes of another set of plaintiffs: investors and employees who filed securities, derivative and ERISA suits against the company. Plaintiffs in 10 cases, consolidated in New Jersey's federal district court, claim they were financially harmed by Merck's marketing of a dangerous drug, and their attorneys say the product liability settlement shows the damages were high. Several of the cases, though, have some obstacles to overcome.
November 15, 2007 at 12:00 AM
1 minute read
The $4.85 billion Vioxx settlement announced last week is bolstering hopes of another set of plaintiffs: investors and employees who filed securities, derivative and ERISA suits against the company.
Plaintiffs in 10 cases, consolidated in New Jersey’s federal district court, claim they were financially harmed by Merck & Co.’s marketing of a dangerous drug, and their attorneys say the product liability settlement shows the damages were high.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
